Targeting KIF20A to treat glioblastoma
Investigating KIF20A as a therapeutic target in glioblastoma
This study is looking at a protein called KIF20A to see if blocking it can help kill glioblastoma cells, which could lead to new treatment options for patients with this tough brain tumor.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10947506 on NIH RePORTER |
What this research studies
This research investigates the role of KIF20A, a protein involved in cell division, as a potential therapeutic target for glioblastoma, an aggressive brain tumor. The study aims to explore how inhibiting KIF20A can lead to the death of cancer cells, particularly using small molecules and CRISPR technology. By understanding the effects of KIF20A on cell viability and mitotic processes, the research seeks to develop new treatment strategies that could overcome the limitations of current therapies. Patients with glioblastoma may benefit from this innovative approach that targets a specific vulnerability in their cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those with IDH-wild-type tumors.
Not a fit: Patients with other types of brain tumors or those who do not have glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Summers, Matthew K — Ohio State University
- Study coordinator: Summers, Matthew K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.